Von Willebrand Disease Pathophysiology and Management

Von Willebrand disease (VWD) arises from quantitative or qualitative defects in von Willebrand factor (VWF), a large multimeric glycoprotein essential for primary haemostasis and for stabilising coagulation factor VIII. Under normal conditions, VWF is synthesised in endothelial cells, assembled into multimers, stored in Weibel-Palade bodies and secreted into plasma. In VWD subtypes, mutations may impair synthesis (type 1), disrupt multimer assembly or binding to platelet glycoprotein Ibα (type 2) or abolish VWF expression entirely (type 3). Abnormal VWF function leads to mucocutaneous bleeding, menorrhagia and, in severe cases, joint or muscle bleeds. Management combines local measures, desmopressin-induced release of endogenous VWF, plasma-derived or recombinant VWF concentrates and adjunctive antifibrinolytic agents. Prophylactic regimens, tailored to bleeding phenotype and surgical requirements, improve outcomes. Emerging insights into VWF mechanobiology, expression heterogeneity and endothelial crosstalk are informing next-generation therapies and personalised diagnostic pathways.

Research from Nature Portfolio

Recent investigations have elucidated the two-step conformational activation of VWF under flow. Single-molecule imaging in microfluidic assays revealed that VWF elongates from a compact to a linear form and, under sufficient tensile force, undergoes a local transition exposing high-affinity sites for platelet glycoprotein Ibα. This hierarchical mechano-regulation explains how VWF activates at sites of vascular injury yet remains quiescent in normal circulation.

Studies of endothelial mosaicism have shown that VWF expression is not uniform but switches stochastically between active and silent states via an epigenetic bistable mechanism. Dynamic heterogeneity in Weibel-Palade body content across the vasculature may underlie differential susceptibility to bleeding or thrombosis and suggests adaptive homeostatic control of haemostatic reserves.

Von Willebrand Disease Pathophysiology and Management publication trend

The graph below shows the total number of articles in von willebrand disease pathophysiology and management across all publications each year (not limited to Nature Index journals).

Technical terms

Weibel-Palade bodies (WPBs): specialised endothelial storage granules containing VWF and P-selectin, released upon stimulation.

von Willebrand factor (VWF): multimeric glycoprotein mediating platelet adhesion under shear and chaperoning factor VIII.

Glycoprotein Ibα (GPIbα): platelet receptor that binds unfolded VWF A1 domains to initiate adhesion.

Shear stress: force exerted by blood flow on vessel walls, driving VWF conformational changes and platelet recruitment.

Desmopressin: synthetic vasopressin analogue that stimulates endothelial release of stored VWF.

Replacement therapy: administration of plasma-derived or recombinant VWF concentrates to restore haemostatic function.

Epigenetic bistable switch: regulatory mechanism of DNA methylation that enables dynamic on/off gene expression states.

References

1. Evoked Weibel‐Palade Body Exocytosis Modifies the Endothelial Cell Surface by Releasing a Substrate‐Selective Phosphodiesterase. Advanced Science (2024).
2. FRET Visualization of High Mechanosensation of von Willebrand Factor to Hydrodynamic Force. Biosensors (2025).
3. Flow-induced elongation of von Willebrand factor precedes tension-dependent activation. Nature Communications (2017).
4. A role of stochastic phenotype switching in generating mosaic endothelial cell heterogeneity. Nature Communications (2016).
5. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. Journal of Thrombosis and Haemostasis (2013).
6. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere (2019).
7. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine (2021).